Evidence Based Strategies for Effective Skin Antisepsis: An HAI Prevention Approach

> FRAN CANTY, M.A., B.S.N., R.N., VA-BC Medical Science Liaison PDI Healthcare

> > Disclosures

PDI Healthcare Employee

Objectives

- Discuss the impact of contamination of the skin on the risk for HAI
- Review the FDA's Tentative Final Monograph for skin antiseptics
- Review the evidence-based methods to reducing CLABSI
- Discuss the standard evaluation questions to consider when evaluating skin antiseptics







Self Check

"So with all of the evidence based practices that exist for the prevention of HAIs, why do most healthcare facilities fail to utilize these recommendations approximately 60% of the time?"

Consumers Union

The Importance of a Checklist



WHO Checklist for Safer Surgical Care



Healthcare-Associated Infections (HAIs)

- 1 out of 25 hospitalized patients affected
- Associated with increased mortality
- Attributed costs: \$26-33 billion annually
- HAIs occur in all types of facilities, including:
 - Long-term care facilities
 - Dialysis facilities
 - Ambulatory surgical centers
 - Hospitals



How do you view life?



How do you view mortality?







Outbreaks vs. Endemic Problems

- Endemic problems represent the majority of HAIs
- Device-associated infections
 - Catheter-associated urinary tract infections (CAUTI)
 - Central line-associated Blood stream infections (CLABSI)
 - ventilator-associated Pheumonia (VAP)
- Procedure-associated infections
 Surgical site infections (SSI)
- Adherence problems
- - Hand hygiene
 - Isolation precautions



Healthcare has moved beyond hospitals



Challenges of Tomorrow

- Decreasing Reimbursement
- Evolving Technological Needs
- Resistant Microbes
- Antimicrobial Resistance
- Higher Acuity
- Staffing
- Transparency
- Public Reporting

Physiology of the Skin

Illustration of Cross-section of Human Skin



- Skin is composed of two layers

 -epidermis & dermis

 Bacterial flora are on and
 within the epidermis, hair
 follicles, sweat & sebaceous
- Dermis and subcutaneous tissue are free of microbial flora

glands

Patient Preoperative Skin Preparation

Label Indication:

- Helps reduce bacteria that potentially cause skin infection.
- For the preparation of the skin prior to surgery.
- For the preparation of the skin prior to injection.

Testing Process:

- Measures immediate and persistent reduction after single treatment.
- Nonprescription Drugs AC Meeting March 23, 2005



TFM Endpoints:

Bacterial Reduction (log₁₀) 1-log CFU / pre-injection 2-log CFU / abdomen (dry site) 3-log CFU / groin (moist site)

Patient Preoperative Skin Preparation Methodology

- Inclusion / Exclusion
- Washout period for 14 days
- No bathing 24 hrs prior to baselines
- Baseline screening counts
- Pre-injections \geq 1.0 x 10³
- Large enough to show
 ≥ 2 log for Abdomen (dry site)
 ≥ 3 log for Groin (moist site)

Nonprescription Drugs AC Meeting March 23, 2005



Patient Preoperative Skin Preparation (Abdominal Site)

- Application of prep formulation
- Cover area with a sterile gauze pad



Nonprescription Drugs AC Meeting March 23, 2005

Patient Preoperative Skin Preparation

Surgical Scrub	Industry Coalition's Proposal Reduction (log ₁₀)	FDA TFM Proposal Reduction (log ₁₀)
Pre-injection	1	1
Abdomen	1 (No persistence criteria)	2 (persistence*)
Groin	2 (No persistence criteria)	3 (persistence*)
* <u>Persistence</u> : prolor prevents or inhibits	ged or extended antimicrobia the proliferation or survival	al activity that of microorganisms after



Industry Coalition's Comments

TFM Criteria

- "overly stringent"
- inappropriate in antiseptic products with proven clinical benefit because they cannot meet the current criteria.
 - Monograph: alcohol & iodine
 - NDA: chlorhexidine gluconate
- all antiseptic products only need to be effective after a single use.

Nonprescription Drugs AC Meeting March 23, 2005

Current utilization

- Pre-Operative Skin Antiseptics:
 - Vascular Access
 - PICC Line Insertion
 - Traditional Operating RoomHips, CABG, etc.
 - Cardiac Catheterization
 - Femoral Catheter Insertion
 - Special Procedures
 - Primary Care and Ambulatory Surgery
 - Minor Knee Repairs, Excisions and Biopsies, etc.
 - Site Maintenance
 - Orthopedic Pin Care
 - Dressing Changes

Nonprescription Drugs AC Meeting March 23, 2005

Back to the Basics

- Aseptic Technique is a set of specific practices and procedures performed under carefully controlled conditions with the goal of minimizing contamination by pathogens
- · Goals of skin antisepsis:
 - Designed to minimize exposure to pathogenic organisms (both intrinsic and extrinsic)
 - Reduce the likelihood of infection
 - Prevent spread of pathogen

Nonprescription Drugs AC Meeting March 23, 2005

24

22

Properties of an Ideal Antiseptic

- Broad Spectrum
- Quick
- Ease of Use for Clinician
- Persistence
- Maintain activity in the presence of organic matter
- Non-irritating

Nonprescription Drugs AC Meeting March 23, 2005

2013 AORN Guideline

- Nonscrubbed personnel should apply the skin antiseptic. The risk of contamination to sterile gown and gloves is high, in most circumstances, when scrubbed personnel perform the prep.
- Sterile gloves should be worn unless the antiseptic prep applicator is of sufficient length to prevent the antiseptic and patient's skin from contact with the nonsterile glove



26

🗞 AOR N

Nonprescription Drugs AC Meeting March 23, 2005





Potential Risk Factors:

What are the concerns of IPs and Vascular Access Professionals?

Table 1-2. Intrinsic and Extrinsic Risk Factors for CLABSI

Intrinsic Risk Factors (nonmodifiable characteristics of the patient)	Extrinsic Risk Factors (potentially modifiable factors associated with CVC insertion or maintenance)
Patient's age	Prolonged hospitalization before CVC insertion
Underlying diseases or conditions	Multiple CVCs
Patient's gender	Parenteral nutrition
	Femoral or internal jugular access site
	Heavy microbial colonization at insertion site
	Multilumen CVCs
	Lack of maximal sterile barriers for CVC insertion
	CVC insertion in an ICU or emergency department

Sample Core Questions to Ask

- Is your product FDA registered/approved? If so, what is the FDA registration number?
- Are there any independent studies available supporting the efficacy of your product?
- Is it broad spectrum?
- Is it non-irritating?
- · Is it compliant with the CDC EBP?
- What value-adds are available to enhance compliance, improve outcomes, and decrease cost?
- Is it aligned with the healthcare reform outcome measures?

Nonprescription Drugs AC Meeting March 23, 2005

Transient vs. Resident Skin Flora

- Transient flora is found on and within the epidermal layer of the skin.
 - -Almost all disease-producing microorganisms belong to this category -Is easily removed with proper skin prep and hand hygiene
- Resident flora is found in the dermis of the skin
 -Removal is more difficult

Antimicrobial Log Reduction Explained

- Log reduction in easy terms:
 - 1 log₁₀ = reduced by 90%
 (90% of 100,000 organisms = 90,000 killed, leaves 10,000 on skin)
 - 2 log₁₀ = reduced by 99%
 - 3 log₁₀ = reduced by 99.9%
 - 4 log₁₀ = reduced by 99.99%

Nonprescription Drugs AC Meeting March 23, 2005

Antimicrobial Log Reduction Explained

- Log reduction is the number of organisms reduced by the effect of an antiseptic
- $1 \log_{10} = 10^1$
- $2 \log_{10} = 10^2$
- $3 \log_{10} = 10^3$
- Ex. 100,000 S. epidermidis on skin
 - After 1 log₁₀ reduction = 10,000 bacteria left
 - After 2 log₁₀ reduction = 1,000 bacteria left
 - After 3 log₁₀ reduction = 100 bacteria left

Nonprescription Drugs AC Meeting March 23, 2005

FDA regulated antiseptics

- Isopropyl Alcohol
- PVP/lodine
- PCMX
- · Chlorhexidine gluconate

Antiseptic Agents for Skin Preps									
Agent	Action	Gram Pos	Gram Neg	MTb	Fungi	Virus	Rapid Action	Resid. Action	Toxic
Alcohol	Denatur e Protein	Excellen t	Excellent	Good	Good	Good	Most Rapid	None	Drying Volatile
CHG	Disrupt Cell Membra n	Excellen t	Good	Poor	Fair	Good	Intermed	Excellent	Ototoxic Keratitis
lodine/ PVP	Oxid- ation Sub. Free prot.	Excellen t	Good	Good	Good	Good	Intermed	Minimal	Absorb from skin with possible toxic skin reaction

_		

Is it?

- Safe for the Patient
- · Safe for the User
- Safe for the Skin
- Safe for the Environment

Nonprescription Drugs AC Meeting March 23, 2005

FDA Questions for Skin Antiseptics

- Is the product FDA approved as a skin antiseptic?
- What approvals does the product have? Preinjection or Preoperative?
- What is the wet prep time vs. dry prep time?
- What efficacy claims does the product have?
- Is the product compliant with the CDC Guidelines for Prevention of Intravascular Catheter Related Infections?

Impact of Neonatal CLABSI

- Inherent risk with CVCs
- Difficult to identify and treat
- Prolonged & often frequent exposure to antibiotics
- Major contributor of morbidity and mortality
- Increased length of stay and hospital costs
- Infants are especially vulnerable
- Standardization of Procedures



Holistic Bundled Approach

The Debate of CHG in Neonates



Summary of US Clinical Guidelines for Skin Antisepsis Skin Antisepsis Recommen

Organization and Guideline Centers for Disease Control and Prevention: Guidelines for the Prevention of Intravascular Catheter-Related Infections, 2011

Infusion Nurses Society (INS): Infusion Nursing Standards of Practice, 2011

Society for Healthcare Epidemiology of America (SHEA): Strategies to Prevent Central-Line Associated Bloodstream Infections in Acute Care Hospitals

The Joint Commission: 2011 National Patient Safety Goals for Hospitals

Infectious Diseases Society of America (IDSA): Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Disease: Society of America

APIC Guide to the Elimination of Catheter-Related Bloodstream Infections, 2009 APIC Guide to the Elimination of Infections in Hemodialysis, 2010

SATE AND SEPSES RECOMMENDATIONS Prepare claim situ a 30.5% closeline proparation with alcoho before central venous catheter and peripheral arterial catheter insertion and during dressing changes of there is a contraincation to chohore-doing, include of loading, an indephore, or 70% alcoho can be used as alternatives. **Category IA** Prepare claim situ with an antispeti ("O'Ra lichoh, Inclure" of lodine, an indophor or chlorhexidine gluconate) before peripheral venous catheter insertion. **CategoryIB**

Chlorhexidine solution is preferred for skin antisepsis. One percent to two percent tincture of lodine, lodophor, and 70% alcohol may also be used. Chlorhexidine is not recommended for infants under 2 months of age.

Use a chlorhexidine-based antiseptic for skin preparation in patients older than 2 months of age (A-I) 43-46; Before catheter insertion, apply an alcoholic chlorhexidine solution containing a concentration of chlorhexidine gluconate greater than 0.5% to the insertion site.

Use an antiseptic for skin preparation during central venous catheter insertion that is cited in scientific literature or endorsed by professional organizations.

Skin preparation for obtaining percutaneously drawn blood samples should be performed carefully, with use of either alcohol or tincture of lodine or alcoholic chlomkading ergetart ban 0.55 C/G, raher than powidonecidane; Skin preparation with either alcohol, alcoholic chlomkadine (>0.5%), or tincture of lodine (10%) leads to lower blood culture contamination rates than does the use of powdone-oldine.

Although a preparation containing a concentration of alcoholic chlorhexidine gluconate greater than 0.5% is preferred, tincture of iodine, an iodophor, or 70% alcohol can be used

For patients older than 2 months, a skin preparation solution containing greater than 0.5% chlorhexidine gluconate and 70% isopropyl alcohol should be applied to the insertion site and allowed to dry before the skin is punctured.

Summary of US Clinical Guidelines for Port/Hub Cleansing

Organization and Guideline Centers for Disease Control and Preventio Guidelines for the Prevention of Intravase Catheter-Related Infections, 2011 www.cdc.gov

Infusion Nurses Society (INS): Infusion Nursing Standards of Practice, 2011 www.ins1.org

Infectious Diseases Society of America (IDSA): Clinical Practice Guidelines for the Diagnosis and Management of Intraviscular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America

APIC Guide to the Elimination of Infections in Hemodialysis, 2010 www.apic.org

Port/Hub Cleansing Recommendations Nonine account of the barrowing recommendation of the appropriate anisoptic (hindreadine, powidone lodine, an indoptio, or 70% alcoho) and accession the port only with a teref devices. Appointed disinfectaments must be used to prevent transmission of microbes through connectors. Some studies have shown that disinfection of the devices with chichendine/alcohol solutions appears to be most effective in reducing colonization.

The needless connector should be consistently and thoroughly disinfected using alcohol, tincture of iodine, or chlorhexidine gluconate/alcohol combination prior to each access. The optimal technique or disinfection time frame has not been identified. Disinfect catheter hubs, needleless connectors, and injection ports before accessing the catheter (B-II). Before accessing catheter hubs or injection ports, clean them with an alcoholic chlorhexidine preparation or 70% alcohol to reduce contraducible.

Society for Healthcare Epidemiology of America (SHEA): Strategies to Prevent Central-Line Associated Bloodstream Infections in Acute Care Hospitals www.shea-online.org The Joint Commission: 2011 National Patient Safety Goals for Hospitals

Use a standardized protocol to disinfect catheter hubs and injection ports before accessing the ports.

If a blood sample is obtained through a catheter, clean the catheter hub with either alcohol or tincture of iodine or alcoholic chlorhexidine (>0.5%), allowing adequate drying to mitigate blood culture contamination (A-I).

Disinfect IV ports prior to accessing, using friction and 70% alcohol, iodophor, or chlorhexidine/alcohol agent. Allow to dry prior to accessing.

Survey of Neonatal CHG Use

- Survey of Neonatology Fellowship Directors in the United States
- 61% reported use of CHG for skin antisepsis for neonates
 - 51% limited use on basis of birth weight, gestational age or chronological age.
 - Skin reactions (erythema, erosions, burns) occurring primarily in those weighing <1500 grams were reported by 51%.
 - No difference in adverse events between the
 - alcoholic or aqueous CHG preparations
 - Tamma, Aucott, & Milstone, 2010

FDA Releases New Labeling

"Directions" section of the Drug Facts label

Add the following direction (if there is no language currently on the label regarding use in infants) or replace current directions related to use in infants to read:

 Use with care in premature infants or infants under 2 months of age. These products may cause irritation or chemical burns.





State of prevention knowledge and science

- Guidelines developed for each type of infection and based on systematic reviews of medical literature
 - Prevention of central line-associated blood stream infections
 - Prevention of catheter-associated urinary tract infections
 - Prevention of surgical site infections
 - Prevention of healthcare-associated pneumonia
 - Management of multidrug-resistant organisms
- Recommendations graded according to evidence
- Guidelines contain many recommendations
- Current efforts to help prioritize interventions that are most effective

Adherence to infection control guidelines is incomplete

- Many HAIs are preventable with current recommendations
- Failure to use proven interventions is unacceptable
- Only 30%-38% of U.S. hospitals are in full compliance
- Just 40% of healthcare personnel adhere to hand hygiene
- Insufficient infection control infrastructure in nonacute care settings has allowed major lapses in safe care



Local success fuels national prevention



The need for HAI prevention research



Need for complete implementation of practices known to prevent HAIs

Need for ongoing research to identify new strategies to prevent the remaining



INFECTION PREVENTION IT'S IN YOUR HANDS









Hypothetical ?

- If you knew.....
- That you could do something simple, easy, cost effective, and that was
- Evidence-Based, but took a little extra time.....
- Would you do it????? If it saved a life.....

Questions

- How will you approach Infection Prevention differently within your own practice setting?
- Contact Information:
 - Email: Fran.Canty@pdihc.com
 - Phone: (845) 323 0375